This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The incidence of type 2 diabetes was reduced by 56% in women who took troglitazone on the TRIPOD study (GCRC Protocol #729). That drug is no longer available for clinical use. The present project is a 4-year open label study in which all women who participated in TRIPOD will be given another thiazolidinedione drug, pioglitazone . The primary outcome variable will be the diabetes incidence rate in women who were diabetes free at the end of TRIPOD. That rate will be compared to the rate observed in the placebo arm of TRIPOD, since the rate was increasing linearly in patients followed for up to five years and many patients remained diabetes free either on troglitazone or on placebo at a shorter interval of follow-up .
Showing the most recent 10 out of 565 publications